This site contains promotional information intended only for healthcare professionals resident in the United Kingdom
Sign in
Sign In or Register
Sign out

Information relating to specific disease areas aligned to Pfizer’s portfolio and other resources designed for Pfizer medicines.

See all Therapy areas

Explore Content

The content of this website has been produced in line with the BESPONSA®▼ (inotuzumab ozogamicin) Summary of Product Characteristics for Great Britain and is intended for Healthcare Professionals based in Great Britain. BESPONSA▼ Prescribing Information for Great Britain click here. BESPONSA▼ Prescribing Information for Northern Ireland click here. Adverse event reporting information can be found at the bottom of the page.

Safety Data

BESPONSA offers a well-characterised and manageable safety profile1​​​​​​​

Most common (≥20%) adverse reactions:

  • Thrombocytopenia (51%)
  • Neutropenia (49%)
  • Infection (48%)
  • Anaemia (36%)
  • Leukopenia (35%)
  • Fatigue (35%)
  • Haemorrhage (33%)
  • Pyrexia (32%)
  • Nausea (31%)
  • Headache (28%)
  • Febrile neutropenia (26%)
  • Increased transaminases (26%)
  • Abdominal pain (23%)
  • Increased gamma-glutamyltransferase (21%)
  • Hyperbilirubinaemia (21%)

Most common (≥2%) serious adverse reactions (Grade ≥3):

  • Infection (23%)
  • Febrile neutropenia (11%)
  • Haemorrhage (5%)
  • Abdominal pain (3%)
  • Pyrexia (3%)
  • VOD/SOS (2%)
  • Fatigue (2%)
To consult the Besponsa Summary of Product Characteristics to see a full list of adverse events, please click here

Developments in Leukaemia Care

Watch Professor David Marks discuss targeted therapies and the INO-VATE study, including 3 year follow up and impact of allogeneic bone marrow transplantation on survival

Learn More

Key data from the INO-VATE study

Hear Dr. Anna Castleton discuss the key data for BESPONSA vs standard care from the INO-VATE study

Learn More

* SOS, sinusoidal obstruction syndrome; VOD, veno-occlusive disease.
 This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. See section 4.8 of the SmPC for how to report adverse reactions.
Reference
  1. BESPONSA Summary of Product Characteristics for Great Britain click here. BESPONSA Summary of Product Characteristics for Northern Ireland click here.
PP-INO-GBR-0546. August 2021

Support and resources

Access Support and Resources to read the guidelines or watch videos from leading specialists.

Access here

For UK Healthcare Professionals*

These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.

I confirm that I am a healthcare professional* resident in the United Kingdom.

If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.

*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.

PP-PFE-GBR-3863. November 2021

Yes

No

OK, We will need you to sign in before we can determine if you are aligned with a Pfizer promotional colleague.This is an interstitial message to prompt a HCP before they login.

If you have already registered with pfizerpro.co.uk and select ‘yes’, you will be directed to the sign-in page where you will be required to enter your username and password.

Would you like to register or sign in now?